Status:

COMPLETED

Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)

Lead Sponsor:

Quark Pharmaceuticals

Collaborating Sponsors:

Pfizer

Conditions:

Age-Related Macular Degeneration

Eligibility:

All Genders

50+ years

Phase:

PHASE1

Brief Summary

The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD

Detailed Description

Dose escalation safety study

Eligibility Criteria

Inclusion

  • Patient is ≥ 50 years old and in general good health. Patients with medically controlled chronic disease such as HTN, AODM, and hyperlipidemia may be included.
  • Patient is capable of giving consent.
  • Patient is willing and able to comply with the visit schedule and study procedures including follow-up visits.
  • Patient has documented CNV secondary to AMD with evidence of active disease characterized by blood vessel leakage or evidence of hemorrhage.
  • Patient has clear ocular media and adequate pupil dilation to allow good quality imaging by fundus photography.
  • Patient's intraocular pressure is ≤ 25 mmHg

Exclusion

  • Patient is of childbearing potential. Every female patient is considered of child-bearing potential unless she has had sterilization surgery or is post-menopausal and has not had a menstrual period for at least 12 months.
  • Patient has CNV due to causes other than AMD, including ocular or periocular infections.
  • Patient has lesions not easily imaged and quantified.
  • Patient has underlying systemic disease such as cardiac, neurological, infectious disease, uncontrolled diabetes mellitis, or disease of the eye other than AMD. Patient may have medically controlled glaucoma.
  • Patient is participating in any concurrent interventional study.

Key Trial Info

Start Date :

February 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2010

Estimated Enrollment :

54 Patients enrolled

Trial Details

Trial ID

NCT00725686

Start Date

February 1 2007

End Date

November 1 2010

Last Update

October 10 2012

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Pfizer Investigational Site

Beverly Hills, California, United States, 90211

2

Pfizer Investigational Site

Pasadena, California, United States, 91105

3

Pfizer Investigational Site

Walnut Creek, California, United States, 94598

4

Pfizer Investigational Site

Miami, Florida, United States, 33136